Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339195 | 0.88 | MAPT (0.53) | CYP1A2CYP2C9CYP2C19CYP3A4HTR2A | |
| SCHEMBL1338894 | 0.82 | GAA (0.72) | CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7005212 | 0.82 | MAOB (0.57) | CYP1A2CYP2C19ALDH1A1GAAMAOA | |
| SCHEMBL641262 | 0.81 | MAPT (0.71) | CYP1A2CYP2C9CYP2C19CYP3A4HTR2A | |
| SCHEMBL3041614 | 0.81 | MAPT (0.52) | CYP1A2CYP2C9CYP2C19CYP3A4SLC6A4 | |
| SCHEMBL1341568 | 0.81 | L3MBTL1 (0.64) | CYP1A2CYP2C9CYP2C19CYP3A4SLC6A4 | |
| SCHEMBL31120710 | 0.81 | L3MBTL1 (0.67) | CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL29382755 | 0.80 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL3114464 | 0.80 | CYP1A2 (0.67) | CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1 | |
| SCHEMBL7405348 | 0.79 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19CYP3A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118388379-A | Organic total synthesis method of nimesulide derivative | 大连理工大学 | 2024-07-26 | — | — | CN | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
| WO-2007036785-A2 | CARBON-ISOTOPE MONOXIDE LABELING OF DAA1106 AND ITS ANALOGUES TO BE USED AS TRACERS FOR A PERIPHERAL TYPE BENZODIAZEPINE BINDING SITE | GE HEALTHCARE LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036785-A2 | CARBON-ISOTOPE MONOXIDE LABELING OF DAA1106 AND ITS ANALOGUES TO BE USED AS TRACERS FOR A PERIPHERAL TYPE BENZODIAZEPINE BINDING SITE | GE HEALTHCARE LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| CN-1279044-C | Non-steroidal progesterone receptor modulators | AKZO NOBEL NV (NL) | 2006-10-11 | — | — | CN | disclosed |
| US-20050171087-A1 | Non-steroidal progesterone receptor modulators | MERCK SHARP & DOHME B.V. (NL) | 2005-08-04 | — | — | US | disclosed |
| CN-1649879-A | Non-steroidal progesterone receptor modulators | AKZO NOBEL NV (NL) | 2005-08-03 | — | — | CN | disclosed |
| EP-1495030-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Akzo Nobel N.V. (NL) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084963-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | AKZO NOBEL N.V. (NL) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | CYP1A2 610/4885CYP2C9 1296/4885CYP2C19 709/4885 |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | CYP1A2 3078/4885CYP2C9 1752/4885CYP2C19 1836/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | CYP1A2 2918/4885CYP2C9 1663/4885CYP2C19 1827/4885 |
| US-20050171087-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | CYP1A2 159/4885CYP2C9 280/4885CYP2C19 76/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | CYP1A2 228/4885CYP2C9 601/4885CYP2C19 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.